PubMed=1371813; DOI=10.1093/jnci/84.3.165
Hendrix M.J.C., Seftor E.A., Chu Y.-W., Seftor R.E.B., Nagle R.B., McDaniel K.M., Leong S.P.L., Yohem K.H., Leibovitz A., Meyskens F.L. Jr., Conaway D.H., Welch D.R., Liotta L.A., Stetler-Stevenson W.G.
Coexpression of vimentin and keratins by human melanoma tumor cells: correlation with invasive and metastatic potential.
J. Natl. Cancer Inst. 84:165-174(1992)

PubMed=9973934; DOI=10.1016/S0165-4608(98)00122-8
Nelson M.A., Ariza M.E., Yang J.-M., Thompson F.H., Taetle R., Trent J.M., Wymer J., Massey-Brown K.S., Broome-Powell M., Easton J., Lahti J.M., Kidd V.J.
Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma.
Cancer Genet. Cytogenet. 108:91-99(1999)

PubMed=10952317; DOI=10.1038/35020115
Bittner M., Meltzer P.S., Chen Y.-D., Jiang Y., Seftor E.A., Hendrix M.J.C., Radmacher M.D., Simon R.M., Yakhini Z., Ben-Dor A., Sampas N., Dougherty E.R., Wang E., Marincola F.M., Gooden G.C., Lueders J., Glatfelter A., Pollock P.M., Carpten J.D., Gillanders E.M., Leja D., Dietrich K., Beaudry C., Berens M.E., Alberts D.S., Sondak V.K., Hayward N.K., Trent J.M.
Molecular classification of cutaneous malignant melanoma by gene expression profiling.
Nature 406:536-540(2000)

PubMed=12115485; DOI=10.1002/ijc.10422
Feng Y.-M., Shi J.-Q., Goldstein A.M., Tucker M.A., Nelson M.A.
Analysis of mutations and identification of several polymorphisms in the putative promoter region of the P34CDC2-related CDC2L1 gene located at 1P36 in melanoma cell lines and melanoma families.
Int. J. Cancer 99:834-838(2002)

PubMed=19383853; DOI=10.1158/1535-7163.MCT-08-1030; PMCID=PMC3128982
Su D.M., Zhang Q.-Y., Wang X.-X., He P., Zhu Y.-L.J., Zhao J.-X., Rennert O.M., Su Y.A.
Two types of human malignant melanoma cell lines revealed by expression patterns of mitochondrial and survival-apoptosis genes: implications for malignant melanoma therapy.
Mol. Cancer Ther. 8:1292-1304(2009)